Cargando…

Toxicities of Immunotherapy for Small Cell Lung Cancer

Small cell lung cancer (SCLC), composing 15–20% of lung cancer, is a fatal disease with extremely poor prognosis. In the past two decades, etoposide platinum doublet chemotherapy remained the only choice of therapy, with disappointing overall survival ≤1 year for the metastatic disease. Novel treatm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fu, Yang, Zheng, Yue, Wang, Pei-Pei, Ding, Zhen-Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8200663/ https://www.ncbi.nlm.nih.gov/pubmed/34136376 http://dx.doi.org/10.3389/fonc.2021.603658

Ejemplares similares

Immunotherapy for a POLE Mutation Advanced Non-Small-Cell Lung Cancer Patient
por: Fu, Yang, et al.
Publicado: (2022)

Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer
por: Peng, Yurong, et al.
Publicado: (2023)

Corrigendum: Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer
por: Peng, Yurong, et al.
Publicado: (2023)

Neoantigen: A Promising Target for the Immunotherapy of Colorectal Cancer
por: Zheng, Yue, et al.
Publicado: (2022)

Pre-Immunotherapy Contrast-Enhanced CT Texture-Based Classification: A Useful Approach to Non-Small Cell Lung Cancer Immunotherapy Efficacy Prediction
por: Shen, Leilei, et al.
Publicado: (2021)

Cardiac toxicity in patients with lung cancer receiving thoracic radiotherapy and immunotherapy
por: Son, Christine, et al.
Publicado: (2023)

Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer
por: Xiong, Qi, et al.
Publicado: (2021)

Small cell lung cancer transformation and tumor heterogeneity after sequential targeted therapy and immunotherapy in EGFR-mutant non-small cell lung cancer: A case report
por: Yang, Meng-Hang, et al.
Publicado: (2022)

Cell adhesion molecules and immunotherapy in advanced non-small cell lung cancer: Current process and potential application
por: Yang, Hongjian, et al.
Publicado: (2023)

Immunotherapy in non-small cell lung cancer: Past, present, and future directions
por: Punekar, Salman R., et al.
Publicado: (2022)

Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers
por: Wu, Xinyu, et al.
Publicado: (2023)

Advances in efficacy prediction and monitoring of neoadjuvant immunotherapy for non-small cell lung cancer
por: Wang, Yunzhen, et al.
Publicado: (2023)

Imaging Biomarkers to Predict and Evaluate the Effectiveness of Immunotherapy in Advanced Non-Small-Cell Lung Cancer
por: Liu, Ying, et al.
Publicado: (2021)

Comparative Transcriptomics Unravels Prodigiosin's Potential Cancer-Specific Activity Between Human Small Airway Epithelial Cells and Lung Adenocarcinoma Cells
por: Davient, Bala, et al.
Publicado: (2018)

Metabolomics profiling in prediction of chemo-immunotherapy efficiency in advanced non-small cell lung cancer
por: Mei, Lihong, et al.
Publicado: (2023)

Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR
por: Seegobin, Karan, et al.
Publicado: (2021)

Antiangiogenesis for Advanced Non-Small-Cell Lung Cancer in the Era of Immunotherapy and Personalized Medicine
por: Tabchi, Samer, et al.
Publicado: (2017)

Immunotherapy for extensive-stage small-cell lung cancer: current landscape and future perspectives
por: Zhang, Shuang, et al.
Publicado: (2023)

Predicting response to immunotherapy in non-small cell lung cancer- from bench to bedside
por: Montoya, Chris, et al.
Publicado: (2023)

Immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer
por: Zhang, Xiaofei, et al.
Publicado: (2023)

Investigation of racial differences in survival from non-small cell lung cancer with immunotherapy use: A Texas study
por: Olateju, Olajumoke A., et al.
Publicado: (2023)

Investigation of PALB2 Mutation and Correlation With Immunotherapy Biomarker in Chinese Non-Small Cell Lung Cancer Patients
por: Zhang, Jiexia, et al.
Publicado: (2022)

Evaluation of tumour vaccine immunotherapy for the treatment of advanced non-small cell lung cancer: a systematic meta-analysis
por: Wang, Min, et al.
Publicado: (2015)

Adjuvant immunotherapy in early-stage resectable non–small cell lung cancer: A new milestone
por: Tang, Wen-Fang, et al.
Publicado: (2023)

Potential predictors of immunotherapy in small cell lung cancer
por: Skopelidou, Valeria, et al.
Publicado: (2023)

Comparative Efficacy and Safety of Immunotherapy Alone and in Combination With Chemotherapy for Advanced Non-small Cell Lung Cancer
por: Wang, Xue, et al.
Publicado: (2021)

Major pathological response after neoadjuvant immunotherapy in esophageal spindle cell carcinoma: A case report
por: Fu, Yang, et al.
Publicado: (2021)

Genomic Profiling Reveals Novel Predictive Biomarkers for Chemo-Radiotherapy Efficacy and Thoracic Toxicity in Non-Small-Cell Lung Cancer
por: He, Kewen, et al.
Publicado: (2022)

Impact of Smoking History on Response to Immunotherapy in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Zhao, Wenhua, et al.
Publicado: (2021)

Research Progress on the Microenvironment and Immunotherapy of Advanced Non-Small Cell Lung Cancer With Liver Metastases
por: Fang, Yujia, et al.
Publicado: (2022)

Sex difference in response to non-small cell lung cancer immunotherapy: an updated meta-analysis
por: Liang, Jiali, et al.
Publicado: (2022)

Combining stereotactic body radiotherapy with immunotherapy in stage IV non-small cell lung cancer
por: Liu, Xiaoli, et al.
Publicado: (2023)

Systematic review of the perioperative immunotherapy in patients with non-small cell lung cancer: evidence mapping and synthesis
por: Ni, Yunfeng, et al.
Publicado: (2023)

Indirect comparison between immunotherapy alone and immunotherapy plus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a systematic review
por: Li, Lingling, et al.
Publicado: (2020)

Efficacy and safety of nintedanib in patients with non-small cell lung cancer, and novel insights in radiation-induced lung toxicity
por: Yan, Shu, et al.
Publicado: (2023)

m(6)A regulators featured by tumor immune microenvironment landscapes and correlated with immunotherapy in non-small cell lung cancer (NSCLC)
por: Yuan, Baowen, et al.
Publicado: (2022)

Identification of NLE1/CDK1 axis as key regulator in the development and progression of non-small cell lung cancer
por: Xu, Pei, et al.
Publicado: (2023)

Expression of Microtubule-Associated Proteins in Relation to Prognosis and Efficacy of Immunotherapy in Non-Small Cell Lung Cancer
por: Luo, Jieyan, et al.
Publicado: (2021)

CT-based radiomics in predicting pathological response in non-small cell lung cancer patients receiving neoadjuvant immunotherapy
por: Lin, Qian, et al.
Publicado: (2022)

The Emerging Role of Targeted Therapy and Immunotherapy in the Management of Brain Metastases in Non-Small Cell Lung Cancer
por: Wong, Annick
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_e76j04amn8ciuevnmk666g5ij4